Free Trial

Innoviva (INVA) Stock Price, News & Analysis

$16.13
+0.15 (+0.94%)
(As of 04:27 PM ET)
Today's Range
$16.00
$16.28
50-Day Range
$14.40
$16.19
52-Week Range
$12.22
$16.86
Volume
458,152 shs
Average Volume
661,450 shs
Market Capitalization
$1.01 billion
P/E Ratio
7.27
Dividend Yield
N/A
Price Target
N/A

Innoviva MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
18.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.56mentions of Innoviva in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

710th out of 917 stocks

Pharmaceutical Preparations Industry

332nd out of 427 stocks

INVA stock logo

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

INVA Stock News Headlines

Innoviva Inc INVA
Cosmo Pharmaceuticals NV COPN
3 Lucrative Biotech Stock Buys for Success
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
5/20/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
112
Year Founded
1996

Profitability

Net Income
$179.72 million
Pretax Margin
63.57%

Debt

Sales & Book Value

Annual Sales
$311.59 million
Cash Flow
$3.53 per share
Book Value
$10.66 per share

Miscellaneous

Free Float
61,571,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
0.57

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

INVA Stock Analysis - Frequently Asked Questions

How have INVA shares performed in 2024?

Innoviva's stock was trading at $16.04 at the beginning of the year. Since then, INVA shares have increased by 0.6% and is now trading at $16.13.
View the best growth stocks for 2024 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) issued its earnings results on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a trailing twelve-month return on equity of 28.94% and a net margin of 58.21%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.94%), Westfield Capital Management Co. LP (3.34%), Denali Advisors LLC (0.52%), Principal Financial Group Inc. (0.51%), Hillsdale Investment Management Inc. (0.50%) and Empowered Funds LLC (0.40%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners